Amit Bahl, MD, FRCP, FRCR, FFRRCSI, is Consultant Clinical Oncologist at Bristol Cancer Institute, University Hospitals Bristol, UK, and Clinical Director of Spire Oncology Centre with a special interest in breast and urological cancers. He is the research lead for Uro-oncology at the Bristol Haematology and Oncology Centre. He has led and developed the prostate brachytherapy service at Bristol. He has been an expert adviser to NICE for the technology appraisal on new drugs and an external service reviewer at oncology departments elsewhere in the country.
Prior to his current roles, Professor Bahl became a Member of the Royal College of Physicians (UK) and trained in Clinical Oncology, achieving the Fellowship of the Royal College of Radiologists qualification. He has been awarded the Fellowship of the Royal College of Physicians. He is a current member of the National Cancer Research Institute Clinical Studies Groups for bladder cancer and chairs the penile cancer subgroup. He has been a college tutor of the Royal College of Radiologists for 10 years and has supervised several MD theses in breast and prostate cancer research. He has previously been in the NCRI Renal and Prostate Clinical Studies group. He is an executive committee member of the British Uro-oncology Group.
Professor Bahl is actively involved in research into breast, prostate, bladder and penile cancers. He has more than 100 publications in these research areas and has given several presentations at national and international meetings. In 2012, Professor Bahl was awarded the Cochrane Shanks Jalil Professorship by the Royal College of Radiologists, London and he is Visiting Professor to two international centres and at the University of West of England.
EM-06830 - Date of preparation: March 2019